Society for Clinical Research Sites Welcomes Myoderm as New Global Impact Partner

Ellicott City, M.D., May 11, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Myoderm, a global leader and specialist in sourcing, distribution, and management of comparator drugs and other pharmaceutical products and supplies for clinical research. Myoderm will participate as a Global Impact Partner (GIP) and align with sponsors, CROs and other industry solution providers who share an ongoing commitment to promoting site sustainability across the clinical trials landscape.

“SCRS is pleased to welcome Myoderm as our newest Global Impact Partner,” comments Christine Pierre, SCRS President. “Collaboration with Myoderm will incite dialogue around drug and product sourcing for clinical trials; factors which can affect individual sites. Myoderm has supply chain experience that factors into trial design, and can be shared to gain efficiencies in the processes currently being used.”

“We are honored to be a part of and collaborate with such an innovative organization and group of professionals,” Michael Cohen, Managing Director of Myoderm, remarks. “For more than 25 years we have focused on developing clinical trial supply solutions for sponsors, CROs and research sites alike. We see this partnership as an opportunity to make further advancements to the supply chain, alleviating pressure on research sites and positively impacting patients that benefit from new therapies being developed.”